Earn 10 pts/$1 + 500 bonus points on signup|
Nootropic Pathway Study Kit research kit - MiPeptidos
Nootropic Pathway Study Kit Research Brief
Free download — literature summary PDF
Literature SummaryHPLC DataPMIDs + CitationsEN + ES

No spam. Unsubscribe anytime.

Analytical proof

Batch purity, right where researchers look for it.

Each included compound carries its own HPLC result, batch reference, and testing date so the research brief is backed by real analytical proof.

Semax

Purity (HPLC)

99.3%
HR-SMX-2600315
RP-HPLC C18January 23, 2026

Selank

Purity (HPLC)

99.5%
HR-SLNK-2600115
RP-HPLC C18January 1, 2026

Dihexa

Purity (HPLC)

99.6%
HR-DHX-2600115
RP-HPLC C18January 14, 2026
NeuroscienceSave 12%

Nootropic Pathway Study Kit

Three compounds covering different parts of the cognitive literature

A three-compound cognitive kit organized around attention, stress-response, and synaptic-plasticity research.

Semax is commonly studied in BDNF and attention-related literature
Selank appears in anxiolytic and stress-modulation research
Dihexa is investigated for synaptic-plasticity and connectivity signaling
Built for side-by-side review of distinct neurocognitive pathways
Research Use Only.

Research Use Only. These kits are intended for laboratory research purposes only. Not for human consumption. Public-page summaries reflect published literature and analytical documentation, not human-use instructions or treatment claims.

Kit Bundle
$115.19
$130.90
Save $15.71 (12% off)
Semax (10mg)
$37.95
Selank (10mg)
$32.95
Dihexa (10mg)
$60.00
CoA Included
HPLC Verified
Same-Day Shipping
Third-Party Tested
Secured Transactions· 256-bit SSL
VISA
AMEX
DISC
Pay
Crypto
CoA Included
HPLC Verified
GMP Compliant
Third-Party Tested
Same-Day Shipping
Batch Tracked
Evidence snapshot

Built from published research, not guesswork.

Every public research kit now leads with the proof: cited studies, PMIDs, tracked signals, and batch-level documentation across each component.

Featured journals
Brain ResearchBulletin of Experimental Biology and MedicineJournal of Pharmacology and Experimental Therapeutics
Observation window
12 weeks
Study phases
6
Tracked endpoints
6
Publication span
2001-2013
Featured studies
4
PMIDs on page
4
Research signals
6
COAs included
3
What researchers commonly track

Common measurements, markers, and readouts associated with this research lane in published literature.

BDNF serum levelsGABA activity markersCortisolBDNFSalivary cortisolWorking memory scoresCognitive task scoresPattern recognition
Compound architecture

What is inside the kit, structurally

Core chemistry details pulled from each included compound so the page feels like a real research profile, not a generic bundle card.

Semax

CAS: 80714-61-0

Semax is a synthetic heptapeptide analog of ACTH(4-10) with a stabilizing Pro-Gly-Pro extension. It increases BDNF and TrkB receptor expression, enhances neurotrophic factor signaling, modulates dopaminergic and serotonergic neurotransmission, and provides neuroprotection through antioxidant and inflammatory-pathway mechanisms. Unlike ACTH, Semax has no steroidogenic activity. It improves cerebral circulation, enhances memory consolidation, and has been approved in Russia and Ukraine for stroke recovery and cognitive enhancement.

Molecular formula
C37H51N9O10S
Molecular weight
813.92 Da
Sequence
Met-Glu-His-Phe-Pro-Gly-Pro (heptapeptide; ACTH(4-7) with Pro-Gly-Pro C-terminal extension)

Selank

CAS: 129954-34-3

Selank is a synthetic heptapeptide derived from the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro extension that enhances metabolic stability. It modulates the balance of Th1/Th2 cytokines, influences enkephalinase activity, and increases BDNF mRNA expression in the hippocampus. Selank produces anxiolytic effects comparable to benzodiazepines without sedation, cognitive impairment, or dependence by modulating GABAergic neurotransmission and monoamine metabolism in limbic structures.

Molecular formula
C33H57N11O9
Molecular weight
751.89 Da
Sequence
Thr-Lys-Pro-Arg-Pro-Gly-Pro (heptapeptide; tuftsin analog with Pro-Gly-Pro extension)

Dihexa

CAS: 1401708-83-5

Dihexa is a small, orally active, blood-brain barrier-permeable oligopeptide derivative of angiotensin IV. It acts as an allosteric agonist of the hepatocyte growth factor (HGF)/c-Met receptor system, potentiating HGF signaling at picomolar concentrations. This drives neurogenesis, synaptogenesis, and spinogenesis in the hippocampus. Dihexa is reportedly 10 million times more potent than BDNF in promoting neurite outgrowth. It also enhances synaptic plasticity and long-term potentiation, the cellular basis of learning and memory.

Molecular formula
C27H44N4O5
Molecular weight
504.66 Da
Sequence
N/A (peptidomimetic oligopeptide derived from angiotensin IV; not a standard amino acid sequence)

Published study parameters

Typical dose ranges, intervals, and administration routes cited in the literature for the compounds in this kit.

Research Protocol Notes

Semax and Selank are nasal peptides — no injection needed. Dihexa is administered subcutaneously. All three can be used simultaneously. Published protocols reference morning administration for Semax and Dihexa (focus-related outcomes); Selank is referenced in both morning and evening protocols.

Semax

Morning
Dose ranges cited
200-600mcg
Intervals cited
1-2x daily
Routes cited
Intranasal

Selank

Morning or evening
Dose ranges cited
200-400mcg
Intervals cited
1-2x daily
Routes cited
Intranasal

Dihexa

Morning
Dose ranges cited
0.5-1mg
Intervals cited
Daily
Routes cited
Subcutaneous

These are publication-style study parameters summarized from cited literature and investigational designs. They are provided as research context only, not as human-use instructions or recommendations.

Published Research

Featured peer-reviewed papers supporting the compounds and pairing logic in this kit.

Brain Research2006

Semax, an ACTH(4-10) analogue with nootropic properties, activates BDNF and trkB gene expression in the rat hippocampus

Dolotov OV, Karpenko EA, Inozemtseva LS, et al.

Published data demonstrated Semax produced significant upregulation of BDNF and TrkB receptor gene expression in hippocampal tissue, supporting neurotrophic mechanisms of cognitive enhancement.

PMID: 16386239

Bulletin of Experimental Biology and Medicine2008

Selank administration affects the expression of some genes involved in GABAergic neurotransmission

Zozulya AA, Sizov ME, Tsvetkova IV, et al.

In peer-reviewed research, Selank demonstrated modulation of GABA-A receptor subunit gene expression, providing a molecular basis for its anxiolytic activity without sedative or tolerance-building effects.

PMID: 19145305

Journal of Pharmacology and Experimental Therapeutics2013

Dihexa, a small molecule analog of angiotensin IV, is a potent neurotrophic agent and synaptogenic compound

McCoy AT, Benoist CC, Wright JW, et al.

Literature demonstrates Dihexa was seven orders of magnitude more potent than BDNF at augmenting HGF/c-Met receptor signaling, promoting new synapse formation in published neuronal culture studies.

PMID: 23303219

Bulletin of Experimental Biology and Medicine2001

Neuroprotective effects of Semax in conditions of global cerebral ischemia in rats

Bashkatova VG, Koshelev VB, Fadyukova OE, et al.

Published studies observed significant neuroprotective effects of Semax in ischemic models, with reduced neuronal damage and improved functional recovery markers in animal studies.

PMID: 11687856

What researchers commonly track

Common measurements, markers, and readouts associated with this research lane in published literature.

BDNF serum levels — neurotrophic factor activity
Salivary cortisol — stress response marker
Cambridge Neuropsychological Test Battery — cognitive domains
State-Trait Anxiety Inventory (STAI) — anxiolytic assessment
N-back task performance — working memory capacity
Montreal Cognitive Assessment (MoCA) — global cognition

Observed in the literature

A plain-English view of how published study windows, markers, and reported changes tend to unfold across this research lane.

Week 1Semax · Selank · Dihexa

Neurotrophic Factor Initiation

BDNF serum levelsGABA activity markersCortisol
Published research observed initial upregulation of BDNF mRNA expression within 24-48 hours of Semax administration in animal models
In peer-reviewed studies, Selank demonstrated rapid anxiolytic onset via GABA-A receptor modulation without sedative effects or cognitive dulling
Literature demonstrates Dihexa engagement of the HGF/c-Met receptor system, initiating synaptogenic signaling cascades in published cell-culture data
Weeks 2-3Semax · Selank

BDNF Upregulation & Anxiolytic Consolidation

BDNFSalivary cortisolWorking memory scores
Published research documented sustained BDNF upregulation of 200-400% above baseline in animal models receiving Semax over 14-21 day periods
In peer-reviewed studies, Selank produced measurable reductions in anxiety-related biomarkers including salivary cortisol and state-trait anxiety inventory scores
Literature demonstrates enhanced hippocampal long-term potentiation markers with combined neurotrophic and anxiolytic compound administration
Weeks 4-5Dihexa · Semax

Synaptic Plasticity & Network Formation

Cognitive task scoresPattern recognitionVerbal fluency
Published research observed increased dendritic spine density in hippocampal neurons following Dihexa administration in animal studies
In peer-reviewed studies, the combination of BDNF upregulation (Semax) and HGF/c-Met activation (Dihexa) demonstrated synergistic effects on synaptic connectivity markers
Literature demonstrates measurable improvements in pattern recognition and associative learning tasks in study cohorts during this phase
Weeks 6-7Selank · Semax

Stress Resilience & Emotional Regulation

HPA axis reactivityCortisol awakening responseEmotional regulation
Published research documented enhanced stress-coping markers with reduced HPA axis reactivity in study populations receiving Selank
In peer-reviewed studies, GABA-modulated anxiolytic effects reached stable plateau levels, demonstrating no tolerance development over 6-7 week administration periods
Literature demonstrates modified enkephalin metabolism via Selank's action on carboxypeptidase enzymes, contributing to endogenous opioid system regulation
Weeks 8-10Dihexa · Semax · Selank

Cognitive Performance Consolidation

Executive functionProcessing speedN-back scores
Published research observed consolidated improvements across multiple cognitive domains including executive function, memory encoding, and processing speed
In peer-reviewed studies, Dihexa demonstrated continued synaptogenic activity with measurable increases in hippocampal volume markers in long-term animal studies
Literature demonstrates that combined neurotrophic support produced sustained improvements in N-back task performance and cognitive flexibility measures
Weeks 11-12Semax · Selank · Dihexa

Protocol Completion & Sustained Neuroplasticity

BDNF post-protocolCognitive battery scoresAnxiety inventories
Published research documented maintained cognitive improvements persisting beyond the active administration phase, suggesting structural neuroplastic changes
In peer-reviewed studies, BDNF levels remained elevated above pre-protocol baselines at protocol completion in study cohorts
Literature demonstrates that HGF/c-Met pathway activation produced lasting synaptic connectivity changes detectable in post-protocol assessments

Handling and documentation

Material handling details and batch-level documentation that support clean research workflows.

Water Volume

1 mL bacteriostatic water per 10mg vial (Semax/Selank for intranasal use)

Concentration

10 mg/mL — Semax/Selank: 200-600 mcg intranasal; Dihexa: consult published protocols

Storage

Refrigerate at 2-8°C after reconstitution. Semax/Selank stable 14 days. Dihexa stable 28 days. Do not freeze.

Why this kit exists

Why these compounds are paired in the literature

Plain-English summaries of the mechanisms and published pairings that make this kit coherent for real research work.

1
Semax

Published research shows Semax upregulates BDNF (brain-derived neurotrophic factor) expression, supporting neuroplasticity and synaptic formation in studied models (PMID: 17116167).

2
Selank

Studies indicate Selank modulates anxiolytic pathways without sedative effects, while also showing immunomodulatory activity as a secondary mechanism (PMID: 18577767).

3
Dihexa

Dihexa has been shown in published research to be a potent hepatocyte growth factor modulator, enhancing synaptic connectivity and demonstrating significant effects on memory-related pathways (PMID: 23530037).

Peptide reading

Go deeper on the peptides inside the kit

Article picks tied directly to the compounds in this kit, so researchers can move from the bundle view into peptide-specific literature, mechanism, and handling context.

Browse the full research library

Start Your Research

Get the complete Nootropic Pathway Study Kit at $115.19 — save $15.71 versus purchasing each compound separately. Full COA documentation included with every vial.

Research Use Only. These kits are intended for laboratory research purposes only. Not for human consumption. Public-page summaries reflect published literature and analytical documentation, not human-use instructions or treatment claims.